立体定向放射治疗早期非小细胞肺癌的临床研究  

Clinical study of stereotatic radiotherapy for early stage non-small-cell lung cancer

作　　者：郑灵[1] 陈万泉[1] 郑庆伟[1] 

机构地区：[1]龙岩市第二医院放疗科,福建龙岩364000

出　　处：《临床肺科杂志》2012年第12期2239-2240,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的评价立体定向放射治疗早期非小细胞肺癌的疗效和放射反应。方法 54例Ⅰ期和Ⅱ期(T1,2,3N0M0)非小细胞肺癌患者接受立体定向放射治疗。90%的等剂量曲线覆盖PTV。4 Gy/f共14次或5 Gy/f共10次,每日1次,每周5次。结果 54例患者总有效率为88.89%,其中CR率为25.93%,PR率为62.96%。1年总生存率85.19%,2年总生存率75.93%,3年总生存率66.67%。1年局部无进展生存率79.63%,2年局部无进展生存率68.52%,3年局部无进展生存率53.7%。早期反应主要为一般全身反应、骨髓抑制和肺的早期放射反应,多为Ⅰ-Ⅱ级。晚期放射反应主要为照射区域局限性Ⅰ-Ⅱ级放射性肺炎。结论立体定向放射治疗早期非小细胞肺癌是安全、有效的。Objective To evaluate the clinical effect and radiation of stereotatic radiotherapy for early stage non-small cell lung cancer. Methods A total of 54 stage Ⅰ-Ⅱ non-small cell lung cancer patients were treated by stereotatic radiotherapy. Ttreatment plans required that PTV volumn was covered more than 90% isodose curve. Tumore was given a dose 4Gy/f of totally 14 fractions or 5Gy/f of to- tally 10 fractions once a day and five times a week. Results The overall response rate （ CR ＋ PR） in 54 cases was 88.89%, the com- plete response （CR） rate was 25.93%, the partial response （PR） rate was 62.96%, and the 1,2, 3-year survival rates were 85.19%, 72.22% and 66.67% respectively. The 1, 2, 3-year local progression free survival were 79.63%, 68.52% and 53.7% respectively. The primary radiation reactions are general systemic reactions, marrow depression, and primary lung radiation reaction. Late-course radia- tion reaction is local radiation pneumonia in irradiation region （ degree Ⅰ-Ⅱ）. Conclusion Stereotatic radiotherapy for early stage non- small-cell lung cancer is safe and effective.

关 键 词：早期非小细胞肺癌 放射治疗 立体定向放射治疗 

分 类 号：R734.2[医药卫生—肿瘤]